Clinical TrialOct 19, 2026, 07:11 AM
EyePoint's DURAVYU Wet AMD Trial Misses Primary Endpoint, Meets Secondary
AI Summary
EyePoint, Inc. announced topline results from its Phase 3 LUCIA clinical trial for DURAVYU™ in wet age-related macular degeneration (wet AMD). While the trial did not meet its primary endpoint for statistical non-inferiority in visual acuity, it achieved key secondary endpoints, demonstrating a significant reduction in treatment burden and strong anatomic control. The company also highlighted DURAVYU's favorable safety profile. EyePoint will conduct further analyses to assess next steps for DURAVYU in wet AMD and remains focused on its diabetic macular edema (DME) program, with topline data expected in Q4 2027.
Key Highlights
- EyePoint's DURAVYU Phase 3 LUCIA trial for wet AMD did not meet primary endpoint of non-inferiority in BCVA.
- LUCIA trial met key secondary endpoints, showing a 38% reduction in treatment burden (p<0.0001) and strong anatomic control.
- DURAVYU demonstrated a favorable safety profile with redosing in the LUCIA trial.
- Pooled data from LUGANO and LUCIA trials showed a 40% reduction in treatment burden.
- EyePoint's DME program remains on track, with pivotal Phase 3 topline data expected in Q4 2027.
- The company will conduct further analyses of LUCIA and pooled Phase 3 datasets for DURAVYU's wet AMD potential.
Price Impact
More from EYPT
More in Clinical Trial